Prudential Financial Inc. Has $2.98 Million Position in PAREXEL International Corporation (PRXL)
Prudential Financial Inc. lessened its stake in shares of PAREXEL International Corporation (NASDAQ:PRXL) by 19.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 34,279 shares of the medical research company’s stock after selling 8,070 shares during the period. Prudential Financial Inc. owned about 0.07% of PAREXEL International Corporation worth $2,979,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio raised its holdings in PAREXEL International Corporation by 4.5% during the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after acquiring an additional 73 shares in the last quarter. Meadow Creek Investment Management LLC raised its holdings in PAREXEL International Corporation by 7.1% during the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock worth $125,000 after acquiring an additional 132 shares in the last quarter. Mogy Joel R Investment Counsel Inc. bought a new stake in PAREXEL International Corporation during the second quarter worth about $204,000. Invictus RG bought a new stake in PAREXEL International Corporation during the first quarter worth about $158,000. Finally, BlueCrest Capital Management Ltd bought a new stake in PAREXEL International Corporation during the first quarter worth about $202,000. Institutional investors and hedge funds own 87.45% of the company’s stock.
PRXL has been the topic of several analyst reports. Mizuho upped their target price on PAREXEL International Corporation from $66.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, May 30th. Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 target price on the stock in a report on Thursday, August 31st. BidaskClub lowered PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 target price on the stock. in a report on Tuesday, June 20th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $88.10 price objective on shares of PAREXEL International Corporation in a research note on Wednesday, June 21st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. PAREXEL International Corporation currently has an average rating of “Hold” and an average price target of $75.92.
PAREXEL International Corporation (NASDAQ PRXL) opened at 87.99 on Monday. The stock has a 50 day moving average price of $87.74 and a 200 day moving average price of $78.14. The firm has a market cap of $4.50 billion, a P/E ratio of 42.71 and a beta of 0.79. PAREXEL International Corporation has a 52-week low of $51.16 and a 52-week high of $88.07.
PAREXEL International Corporation (NASDAQ:PRXL) last posted its earnings results on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.08. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. The firm had revenue of $557.20 million for the quarter, compared to analysts’ expectations of $537.59 million. During the same quarter last year, the firm earned $0.94 EPS. Equities analysts predict that PAREXEL International Corporation will post $3.95 earnings per share for the current fiscal year.
PAREXEL International Corporation Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).
Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.